Management of AIDS-Defining Cancers

  • Authors: David Aboulafia, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 4/9/18 (What's New)

Summary

  • PELs are rare HHV8-associated lymphomas that are typically of B-cell origin and arise as a late manifestation of HIV disease[Aboulafia 2004; Raez 1998; Chen 2007]
  • Lymphomatous effusions are exudates that contain high-grade, malignant HHV8-positive lymphoma cells, typically detected by immunostaining
  • Therapy involves a combination of ART, OI prophylaxis, and systemic polychemotherapy[Chen 2007]

Action required

Keywords: Cancer

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.